You are here
Generic Neurontin Gains Approval
Gabapentin is indicated for the management of postherpetic neuralgia in adults. Gabapentin is also indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy and is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 - 12 years.
According to Venkat Krishnan, Vice President, Ranbaxy Inc., "We are delighted to receive final approval for Gabapentin. This product demonstrates Ranbaxy's capabilities to formulate multiple oral product dosage forms." Commenting on the approval, Jim Meehan, Vice President of Sales and Marketing for RPI, stated, "We will launch product immediately and will now be in a position to offer both dosage forms in our product portfolio."
Source: Ranbaxy Pharmaceuticals Inc.